Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase

European Journal of Pharmacology

Volumn 674, Issue 2-3, 2012, Pages 163-170

  Zhang, Li Yuan ^a   Liu, Li Ying ^a   Qie, Ling Ling ^a   Ling, Ka Na ^a   Xu, Li Hua ^a   Wang, Feng ^a   Fang, San Hua ^a   Lu, Yun Bi ^a   Hu, Hua ^a   Wei, Er Qing ^a   Zhang, Wei Ping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

APO866; Glioblastoma; Nicotinamide adenine dinucleotide (NAD); Nicotinamide phosphoribosyltransferase (NAMPT)

Indexed keywords

DAPORINAD; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UO 126;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; M PHASE CELL CYCLE CHECKPOINT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN TARGETING; RAT;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTRACELLULAR SPACE; M PHASE CELL CYCLE CHECKPOINTS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; RATS;

EID: 84855548644     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.11.017     Document Type: Article

References (39)

1. Adya, R., Tan, B.K., Punn, A., Chen, J., Randeva, H.S., 2008. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78, 356-365. (Pubitemid 351556097)
2. Berger, F., Lau, C., Dahlmann, M., Ziegler, M., 2005. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 280, 36334-36341. (Pubitemid 41633907)
3. Bi, T.Q., Che, X.M., 2010. Nampt/PBEF/visfatin and cancer. Cancer Biol. Ther. 10, 119-125.
4. Bi, T.Q., Che, X.M., Liao, X.H., Zhang, D.J., Long, H.L., Li, H.J., Zhao,W., 2011. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor APO866 in combination with fluorouracil. Oncol. Rep. doi:10.3892/or.2011.1378
5. Billington, R.A., Genazzani, A.A., Travelli, C., Condorelli, F., 2008. NAD depletion by APO866 induces autophagy. Autophagy 4, 385-387. (Pubitemid 351458108)
6. Brown, J.E., Onyango, D.J., Ramanjaneya, M., Conner, A.C., Patel, S.T., Dunmore, S.J., Randeva, H.S., 2010. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes inmouse pancreatic beta-cells. J. Mol. Endocrinol. 44, 171-178.
7. Chalmers, A.J., 2010. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med. Chem. 10, 520-533.
8. Chalmers, A.J., Ruff, E.M., Martindale, C., Lovegrove, N., Short, S.C., 2009. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int. J. Radiat. Oncol. Biol. Phys. 75, 1511-1519.
9. Chang, P., Jacobson, M.K., Mitchison, T.J., 2004. Poly(ADP-ribose) is required for spindle assembly and structure. Nature 432, 645-649. (Pubitemid 39626273)
10. Czajkowski, R., Banachewicz, W., Ilnytska, O., Drobot, L.B., Baranska, J., 2004. Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells. Br. J. Pharmacol. 141, 497-507. (Pubitemid 38297012)
11. Drevs, J., Loser, R., Rattel, B., Esser, N., 2003. Antiangiogenic potency of APO866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer. Res. 23, 4853-4858. (Pubitemid 38173905)
12. Erecinska, M., Wilson, D.F., Nishiki, K., 1978. Homeostatic regulation of cellular energy metabolism: experimental characterization in vivo and fit to a model. Am. J. Physiol. 234, C82-C89.
13. Erlich, R.B., Kahn, S.A., Lima, F.R., Muras, A.G., Martins, R.A., Linden, R., Chiarini, L.B., Martins, V.R., Moura Neto, V., 2007. STI1 promotes glioma proliferation through MAPK and PI3K pathways. Glia 55, 1690-1698. (Pubitemid 47612855)
14. Galli, M., Van Gool, F., Rongvaux, A., Andris, F., Leo, O., 2010. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 70, 8-11.
15. Garten, A., Petzold, S., Korner, A., Imai, S., Kiess, W., 2009. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130-138.
16. Hasmann, M., Schemainda, I., 2003. APO866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436-7442. (Pubitemid 37413486)
17. Hayashida, S., Arimoto, A., Kuramoto, Y., Kozako, T., Honda, S., Shimeno, H., Soeda, S., 2010. Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Mol. Cell. Biochem. 339, 285-292.
18. Ho, C., van der Veer, E., Akawi, O., Pickering, J.G., 2009. SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett. 583, 3081-3085.
19. Huang, P.H., Xu, A.M., White, F.M., 2009. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2, re6.
20. Iacob, G., Dinca, E.B., 2009. Current data and strategy in glioblastoma multiforme. J. Med. Life 2, 386-393.
21. Inbar-Rozensal, D., Castiel, A., Visochek, L., Castel, D., Dantzer, F., Izraeli, S., Cohen-Armon, M., 2009. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res. 11, R78.
22. Kang, G.B., Bae, M.H., Kim, M.K., Im, I., Kim, Y.C., Eom, S.H., 2009. Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an APO866-based inhibitor. Mol. Cells 27, 667-671.
23. Katz, M., Amit, I., Yarden, Y., 2007. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 1773, 1161-1176. (Pubitemid 47125978)
24. Lama, G., Mangiola, A., Anile, C., Sabatino, G., De Bonis, P., Lauriola, L., Giannitelli, C., La Torre, G., Jhanwar-Uniyal, M., Sica, G., Maira, G., 2007. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int. J. Oncol. 30, 1333-1342.
25. Lefranc, F., Rynkowski, M., DeWitte, O., Kiss, R., 2009. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv. Tech. Stand. Neurosurg. 34, 3-35.
26. Mangerich, A., Burkle, A., 2011. How to kill tumor cells with inhibitors of poly(ADP-ribosyl) ation. Int. J. Cancer 128, 251-265.
27. Nahimana, A., Attinger, A., Aubry, D., Greaney, P., Ireson, C., Thougaard, A.V., Tjornelund, J., Dawson, K.M., Dupuis, M., Duchosal, M.A., 2009. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113, 3276-3286.
28. Nakajima, T.E., Yamada, Y., Hamano, T., Furuta, K., Gotoda, T., Katai,H., Kato, K.,Hamaguchi, T., Shimada, Y., 2009. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J. Gastroenterol. 44, 685-690.
29. Nishikawa, R., 2010. Standard therapy for glioblastoma - a review of where we are. Neurol. Med. Chir. (Tokyo) 50, 713-719.
30. Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., Kozaki, K., Akishita, M., Ouchi, Y., Kaneki, M., 2006. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25, 176-185. (Pubitemid 43083679)
31. Reddy, P.S., Umesh, S., Thota, B., Tandon, A., Pandey, P., Hegde, A.S., Balasubramaniam, A., Chandramouli, B.A., Santosh, V., Rao, M.R., Kondaiah, P., Somasundaram, K., 2008. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther. 7, 663-668.
32. Revollo, J.R., Grimm, A.A., Imai, S., 2007. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr. Opin. Gastroenterol. 23, 164-170. (Pubitemid 46192971)
33. Romacho, T., Azcutia, V., Vazquez-Bella, M., Matesanz, N., Cercas, E., Nevado, J., Carraro, R., Rodriguez-Manas, L., Sanchez-Ferrer, C.F., Peiro, C., 2009. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52, 2455-2463.
34. Surjana, D., Halliday, G.M., Damian, D.L., 2010. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J. Nucleic Acids 2010. doi:10.4061/2010/157591.
35. Tyagi, A.K., Singh, R.P., Agarwal, C., Chan, D.C., Agarwal, R., 2002. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res. 8, 3512-3519. (Pubitemid 35340729)
36. Wosikowski, K., Mattern, K., Schemainda, I., Hasmann, M., Rattel, B., Loser, R., 2002. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res. 62, 1057-1062.
37. Yao, Y.Q., Ding, X., Jia, Y.C., Huang, C.X., Wang, Y.Z., Xu, Y.H., 2008. Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett. 264, 127-134. (Pubitemid 351602131)
38. Zhang, T., Kraus, W.L., 2010. SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim. Biophys. Acta 1804, 1666-1675.
39. Zohrabian, V.M., Forzani, B., Chau, Z., Murali, R., Jhanwar-Uniyal, M., 2009. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer. Res. 29, 119-123.